Ipamorelin: Research Peptide Guide

For research purposes only. This guide describes the chemical identity and laboratory handling of ipamorelin and summarises findings reported in published research. It is not medical advice and does not describe any effect, dose, or use in humans or animals.

What is ipamorelin?

Ipamorelin (also referenced in the literature as NNC 26-0161) is a synthetic pentapeptide — a chain of five amino acids with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2. It is described in research literature as a selective ligand of the ghrelin / growth-hormone-secretagogue (GHS) receptor, a class of compounds studied for their interaction with the growth-hormone axis in experimental models.

As a research compound, ipamorelin is supplied as a lyophilised (freeze-dried) powder and reconstituted in the laboratory prior to use. PurePeptides offers ipamorelin at greater than 99% purity strictly for in-vitro research. This page describes its chemical identity and handling only and must not be interpreted as describing any effect in humans or animals.

Chemical identity & specifications

Handling ipamorelin in research protocols

In laboratory settings, lyophilised ipamorelin is typically stored at -20°C, protected from light and moisture, until use. For reconstitution, bacteriostatic water is a commonly cited solvent; once in solution, the material is generally kept refrigerated at 2-8°C with freeze-thaw cycles minimised to preserve peptide integrity.

Researchers quantify ipamorelin by concentration within their experimental system — for example molar concentrations for in-vitro work, or amount-per-mass figures in animal models. These are parameters defined by the study design and reported in the literature; they are not dosing guidance for any human or animal use. To convert between vial mass, solvent volume, and target concentration for laboratory preparation, our peptide reconstitution calculator may be useful.

Findings reported in the research literature

Ipamorelin was first characterised in the late 1990s — the foundational description by Raun and colleagues (European Journal of Endocrinology, 1998) introduced it as one of the first peptides reported to act as a selective growth-hormone secretagogue in preclinical models. Subsequent growth-hormone-secretagogue research has referenced ipamorelin as a comparator compound in in-vitro and animal studies.

Any effects described in this literature are observations made in controlled experimental systems — cell assays and animal models — and are reported here only to summarise the scientific record. They do not constitute claims about outcomes, efficacy, benefits, or safety in humans, and nothing on this page should be read as encouraging human or animal use. Readers interested in the primary research can review the indexed literature via PubMed’s ipamorelin results.

Ipamorelin vs. sermorelin vs. CJC-1295

Ipamorelin is often discussed alongside other peptides studied in growth-hormone-axis research. They are chemically distinct, with different sequences, sizes, and receptor targets:

The key distinction researchers draw is mechanism class: ipamorelin acts at the ghrelin / GHS receptor, whereas sermorelin and CJC-1295 (without DAC / Modified GRF 1-29) are GHRH-receptor analogues. All three are supplied by PurePeptides strictly as research materials.

Ipamorelin and the growth-hormone secretagogue family

Ipamorelin belongs to a broader group of compounds known in research as growth-hormone secretagogues (GHS). Within this group, researchers commonly distinguish two mechanistic families: ghrelin / GHS-receptor ligands (the GHRP-type, ghrelin-mimetic peptides) and GHRH-receptor analogues. Ipamorelin sits in the first family, alongside peptides such as GHRP-2, GHRP-6 and hexarelin.

What sets ipamorelin apart in the literature is its reported selectivity. The original characterisation described it as acting on the growth-hormone axis in preclinical models with minimal reported effect on other hormones such as ACTH and cortisol, relative to earlier GHRPs like GHRP-6. For researchers, that selectivity is one reason ipamorelin is frequently chosen as a reference compound in GHS studies. All of these peptides are supplied by PurePeptides solely as research materials, with no claim regarding outcomes in humans or animals.

Purity and quality control in research-grade ipamorelin

In laboratory research, peptide purity has a direct bearing on reproducibility: synthesis by-products or residual reagents can confound experimental observations. PurePeptides supplies ipamorelin at greater than 99% purity as a lyophilised powder.

In peptide manufacturing, purity is typically assessed by reverse-phase high-performance liquid chromatography (HPLC), while identity is confirmed by mass spectrometry (MS) against the expected molecular weight — approximately 711.9 g/mol for ipamorelin. A certificate of analysis (COA) documenting these results is available on request for the current batch. When evaluating any research-grade peptide, requesting the COA and confirming both the purity figure and the mass-spec identity is good laboratory practice.

Frequently asked questions

Research-grade ipamorelin

Greater than 99% purity, lyophilised powder, same-day dispatch before 3PM with tracked UK & EU delivery. Research use only.

Disclaimer: All products supplied by PurePeptides are strictly for laboratory research use only. They are not for human or animal consumption and are not medical products. This guide is informational and summarises publicly available research; it is not medical, clinical, or dosing advice.